IPHA - Innate Pharma

Recent News

Boeing, Nurix Therapeutics And 3 Stocks To Watch Heading Into Monday - Boeing ( NYSE:BA )

With U.S. stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Karooooo Ltd. KARO to report quarterly earnings at 39 cents per share on revenue of $63.23 million after the closing bell, according to ...

Bullish

All You Need to Know About Innate Pharma ( IPHA ) Rating Upgrade to Buy

Zacks Commentary • 1 year, 5 months ago • score: 0.37

Innate Pharma (IPHA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Neutral

Innate Pharma ( IPHA ) Gains as FDA Lifts Hold on Lymphoma Study

Zacks Commentary • 1 year, 8 months ago • score: 0.02

Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.

52W High

$3.51

52W Low

$1.29

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.91

Valuation

As of 2025-03-31 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.94

EV/Revenue (<3 favorable)

9.00

P/S (TTM) (<3 favorable)

9.83

P/B (<3 favorable)

18.34

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

0.17%

Shares Outstanding

92,167,000

Float

59,218,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-03-31 (Overview)

Revenue (TTM)

20,121,000

Gross Profit (TTM)

-31,859,000

EPS (TTM)

-0.71

Profit Margin (>10% good)

-2.46%

Operating Margin (TTM) (higher better)

-3.25%

ROE (TTM) (>15% strong)

-1.63%

EPS YoY (Quarterly) (>10% good)

-0.75

Revenue YoY (Quarterly) (>8% good)

-0.64

Momentum

Value

N/A

Trend

—

Signal Cross

No cross

As of

—